Andrew (“Andy”) Balo is Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom.
Andy assumed the role of Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom in May 2016. In this role, Andy is responsible for overseeing Dexcom’s clinical trials worldwide and developing global regulatory strategies related to these activities.
Since joining Dexcom in 2002, Mr. Balo has held several executive roles, including Executive Vice President, Clinical, Regulatory and Quality, Senior Vice President of Clinical and Regulatory Affairs and Vice President of Clinical and Regulatory Affairs.
Prior to joining Dexcom, Andy served as Vice President of Regulatory and Clinical Affairs for InnerCool Therapies and Endocardial Solutions. Andy also held several leadership positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company.
Andy received his Bachelor of Science degree in Microbiology and Chemistry from the University of Maryland and completed graduate studies at UCLA and Stanford University.
What is Andrew K. Balo's net worth?
The estimated net worth of Andrew K. Balo is at least $1.32 million as of July 6th, 2021. Mr. Balo owns 16,533 shares of DexCom stock worth more than $1,323,301 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Balo may own. Learn More about Andrew K. Balo's net worth.
How do I contact Andrew K. Balo?
Has Andrew K. Balo been buying or selling shares of DexCom?
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 24 times. They sold a total of 248,077 shares worth more than $32,452,099.04. The most recent insider tranaction occured on November, 20th when EVP Sadie Stern sold 4,259 shares worth more than $318,275.07. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 11/20/2024.
